Myeloid zinc finger 1 (MZF1) belongs to the SCAN-Zinc Finger (SCAN-ZF) transcription factor family that has recently been implicated in a number of types of cancer. Although the initial studies concentrated on the role of MZF1 in myeloid differentiation and leukemia, the factor now appears to be involved in the etiology of major solid tumors such as lung, cervical, breast and colorectal cancer. Here we discuss the regulation of MZF1 that mediated its recruitment and activation in cancer, concentrating on posttranslational modification by phosphorylation and sumoylation, interaction with promyelocytic leukemia nuclear bodies and its association with co-activators and co-repressors.
(1) Introduction-MZF1 in cancer Myeloid zinc finger 1 (MZF1 aka MZF1A, MZF1B, ZSCAN6, ZNF42 and ZFP98) is a SCAN-Zinc Finger (SCAN-ZF) transcription factor family member and has been implicated in a number of cancers and cellular malignancies (Hromas, Morris et al. 1995 , Gaboli, Kotsi et al. 2001 , Reymann and Borlak 2008 , Mudduluru, Vajkoczy et al. 2010 , Rafn, Nielsen et al. 2012 , Deng, Wang et al. 2013 ). We will refer here to the human gene or protein as MZF1 ( Fig 2) . Zinc finger proteins have in common the possession of small structural motifs, often occurring in clusters that can coordinate divalent cations such as Zn++, forming finger-like structures that can bind to, most notably the major groove in DNA and permitting sequence-specific binding. MZF1 was first suspected to be involved in malignancy in studies on hematopoietic development along the myeloid lineage. MZF1 appeared to function as a gene repressor in this context, repressing the CD34 or c-myb promoter activity essential for hematopoietic differentiation (Perrotti, Melotti et al. 1995) .
Such a block towards differentiation suggested the emergence of a leukemic phenotype (Perrotti, Melotti et al. 1995) . Neoplastic cell transformation by MZF1 was indeed demonstrated using the NIH3T3 transformation model, and forced expression of MZF1 led to emergence of cells that grew rapidly in vivo and initiated tumors in athymic mice (Hromas, Davis et al. 1996) . Subsequent studies showed that immortalized myeloid cells were protected from IL-3 withdrawal-mediated apoptosis by MZF1 (Hromas 1996) . MZF1 activity again resulted in cells that formed tumors in congenic mice. However, there was some ambivalence in the role ascribed to MZF1 in hematopoietic cancers. Gaboli et al showed that mzf1-/-mice underwent a large increase in autonomous proliferation of hemopoietic progenitors and suggested that the mzf1 gene might function as a suppressor of blood cell cancers (Gaboli, Kotsi et al. 2001) . The reasons for discrepancies were not obvious although they could be connected to the findings that the mzf1 gene can give rise to at least two transcripts that may have contrasting properties in the cell (see below).
The development of other types of solid tumor cancers have subsequently been associated with MZF1. Analysis of data from the TCGA website indicated significant amplification of the MZF1 gene in human breast, uterine, lung and bladder cancers as well as increased levels of mutation in colorectal cancer (Fig.1) . By contrast, in Glioma, a significant number of cancers showed MZF1 deletion (Fig. 1 ). In addition, analysis of mRNA levels in a series of human cancers indicated large increases in MZF1 mRNA in myeloma and cutaneous melanoma compared to normal tissues (Oncomine: https://www.oncomine.org) Likewise MZF1 appeared to play roles in multiple cancers as indicated by studies in cellular and animal models. In experiments in SK-Hep1 HCC tissue culture cells in vitro, inhibition of MZF1 expression using antisense technology led to reduced growth in hepatocellular carcinoma (Hsieh, Wu et al. 2007 ). This finding might not have been predicted from study of human liver tumors in which evidence of MZF1 amplification or mutation was low ( Fig. 1 ). In addition, MZF1 was shown to mediate migration, invasion and in vivo metastasis in colorectal cancer models in vitro (RKO and SW480 cells) and cervical cancer cells (Mudduluru, Vajkoczy et al. 2010) . In these studies the gene for the receptor tyrosine kinase AXL was shown to be activated by MZF1 at the transcriptional level, and knockdown of MZF1 by RNA interference reduced migration and invasion. AXL activity has been associated with a metastatic phenotype (Asiedu, Beauchamp-Perez et al. 2014 ). Moreover, MZF1 and AXL levels were positively correlated and significantly higher in resected colorectal tumors compared to normal tissues (Mudduluru, Vajkoczy et al. 2010 ). In three-dimensional breast cancer model derived from primary human breast cancer, MZF1 was found to bind to the enhancer element and drive the expression of the cathepsin B(CTSB) gene, a key molecule required for tumor invasion (Rafn, Nielsen et al. 2012) Rafn et al were able to define a signaling cascade that was initiated by ERBB2 activation through transforming growth factor receptor RII (TGFRII) binding and propagated by the kinases, CDC42BP, ERK2, PAK4 and PKCA. This study gave the first convincing indication of an activating signaling pathway that might be located upstream of human MZF1 in cancer signaling (see below). A role for the TGFRII ligand, TGF-1 in MZF1 function was likewise indicated by studies showing that TGF- released by MDA_MB-231mammary cancer cells could cause mesenchymal stem cells to differentiate into cancer associated fibroblasts (CAF) in a process dependent on MZF1 (Weber, Kothari et al. 2014) . TGF factors classically regulate transcription through a series of Smad factors that can translocate to the nucleus and modulate gene expression (Derynck and Zhang 2003) .TGF-1 can play paradoxical roles in cancer, in some contexts inhibiting tumor growth although in others triggering cell invasion and local immune suppression (Massague 2008) . Effects on CAF may play a significant role in such TGF-1 functions. In lung adenocarcinoma another mechanism for MZF1 activation has been described (Tsai, Wu et al. 2014) . MZF1 activity was triggered by the loss of Liver Kinase B1 (LKB1) leading to elevated levels of MYC, increased migration and invasion of CL-1 lung adenocarcinoma cells. Loss of LKB1 was shown to be associated with inactivation of the tumor suppressor TP53 and enhanced expression of the lung proto-oncogene protein NK2 homeobox 1 (NKX2-1) (Tsai, Wu et al. 2014) . MZF1 was also reported to be activated downstream of NKX2 in human papillovirus driven cancer. MZF1 led to upregulation of FOXM1 expression, again promoting migration, invasion and stemness that may be related to increase in Wnt /  catenin signaling . Another cancer relevant transcriptional target of MZF1 may be the protooncogene CDC37, which is required for oncogenic kinase maintenance and plays a role in the emergence of prostate carcinoma (Huang, Grammatikakis et al. 1998 , Gray, Prince et al. 2008 . Overexpression of CDC37 drives proliferation, survival and AR activity in prostate cancer, and thus induction of CDC37Cdc37 by MZF1 may have a critical role in development of prostate cancer (Calderwood 2015) .
A recurrent theme in a number of the studies is a role for MYC in association with MZF1, and MYC is one of the factors that can bind the MZF1 gene promoter (Suppl . Table 1 ). MYC appears to be regulated upstream and downstream of MZF1 suggesting a positive feedback loop. It may be significant that MZF1 target CDC37 can synergize with MYC in prostate carcinogenesis in transgenic mouse models (Stepanova, Finegold et al. 2000 , Sironen, Karjalainen et al. 2002 .
Thus changes in expression, mutation and regulation of the MZF1 gene have been implicated in a wide spectrum of cellular malignancies. One common theme running through many of the studies was the finding of MZF1-dependent transcriptional changes associated with malignant cell migration and invasiveness. These effects of MZF1 could be mediated through repression of differentiation factors such as CD34 and c-myb or the trans-activation of genes encoding effector proteins such as AXL and cathepsin B.
Interestingly, the effects of MZF-1 are dependent on cancer type and thus we speculate a specific genetic milieu influence activity of MZF1. Such interactions require further elucidation as might be critical for understanding cancer development as well as design of new therapeutic strategies.
As a whole, these effects of MZF1 appear to be mediated by complex transcriptional networks that require such factors as MYC, FOXM1 and NKX2-1. Consequently, elucidating the function and interactions of MZF1 within this network will require further analysis.
(2) MZF1 as a member of the SCAN-Zinc Finger transcription factor family MZF1 belongs to the SCAN-ZF domain-pair gene cluster and is a component of the larger ZF, 600-member transcription factor family expressed only in vertebrates. The human genome has been shown to contain nearly seventy SCAN-ZF factors, including MZF1 itself (Edelstein and Collins 2005) . SCAN-ZF family members possess a varied number of Cys2His2 zinc finger motifs that bind distinct DNA motifs, giving sequence specific recognition of target genes. In addition a small number of SCAN domain-only (SCAND) factors have been discovered that lack the DNA binding ZF domains and are currently thought to function as regulators of the intact SCAN-ZF factors that may be significant in cancer (Sander, Stringer et al. 2003, Edelstein and Collins 2005) . As a promoter /enhancer-binding-type transcription factor, MZF1 functions as both a trans activator and trans-repressor, suggesting that its relative oncogenic activity may be an aggregate of increases and decreases in gene expression (Edelstein and Collins 2005) .
The MZF1 activating and repressing kinase phosphorylation signals, inter-molecular interactions are transcriptional gene targets are described herein, organized in Table 1 and modeled in Figure 2 .
(3) The MZF1 gene
Understanding the organization of the MZF1 gene and its regulation may give us a window through which to observe its involvement in malignancy. The human MZF1 gene (NCBI Gene ID: 7593) is located on the end of chromosome 19q with its 5' end and promoter oriented towards the telomere, suggesting that telomere shortening in aging cells could affect MZF1 biology. MZF1 encodes two unique isoforms produced by alternative splicing. A third isoform record of alternative transcription initiation was recently found to be an artifact and deleted from NCBI, however the isoform was maintained in the mouse record, thus suggesting a difference in species. The ability of the MZF1 gene to encode multiple transcripts, likely with differing properties may play a significant role in its complex influences on tumorigenesis, as will be discussed below.
The larger MZF1 isoform 1 (NM_03422.2) encodes a longer protein known as both MZF1A and MZF1B producing a 734 aa protein product (NP_003413.2). This factor contains the N-terminal SCAN domain followed by a regulatory linker connected to a C-terminal DNA binding domain containing 13 C2H2-type zinc finger (ZF) motifs. Studies in murine MZF1 place the trans-activation domain (TAD) within this linker region (Murai, Murakami et al. 1997) . A shorter MZF1 isoform 2 (NM_01267033.1) encodes a 290 aa protein product (NP_001253962.1) comprising of the SCAN domain, part of the regulatory linker and a unique C-terminal motif.
Interestingly this unique C-terminal motif lacks the phosphorylation sites predicted to reside in the corresponding region on MZF isoform 1 as well as the C-terminal ZF DNA binding domains, suggesting unique functions for both MZF1 isoform 2 and the phosphorylation of MZF isoform 1 (Figure 2 ) .
The full repertoire of mechanisms of regulation of MZF1 gene expression have yet to be rigorously characterized. However global analysis of the human genome and proteome could provide some insights into the biology of MZF1. Comprehensive ChIP-Seq profiling of 161 transcription factors indicated that the MZF1 gene promoter contained a single RNA polymerase 2 (POLR2A) binding site spanning the transcriptional start site (Hudson and Snyder 2006) (Euskirchen, Rozowsky et al. 2007) . Within this POLR2A footprint 85 different transcription factors were shown to map to 111 binding sites, with 24 such factors binding to more than one site (Suppl Table 1 ). Notable transcription factors included MYC, HSF1, TRIM28, STAT3, RELA, MAX and ZNF143. The observation that MYC bound to the MZF1 gene promoter may be of significance in regulating expression of the MZF1 gene in cancer (as discussed below). Protein profiling of normal human tissue indicated that the MZF1 protein was most highly expressed in the thyroid and brain (Uhlen, Fagerberg et al. 2015 ) (Uhlen, Bjorling et al. 2005 ) (www.proteinatlas.org).
(4) Regulation of MZF1 Function
The intracellular mechanisms of MZF1 regulation are largely uncharacterized but examination of the available data suggested a number of levels of regulation including posttranslational modifications, dynamic intra-nuclear localization, protein-protein association and binding to transcriptional co-factors.
(5) MZF1 and promyelocytic leukemia nuclear bodies (PML-NBs)
MZF1 has been shown to concentrate in PML-NBs (Bernardi and Pandolfi 2007 , Heun 2007 , Noll, Peterson et al. 2008 
MZF1 Regulation by SUMO modification
MZF1 was shown to co-associate with PML-NB protein PML, a member of the tripartate motif family and the principle coordinator of PML-NB assembly, within the nuclear bodies through its N-terminal region as determined using immunofluorescence analysis (Jensen, Shiels et al. 2001 , Noll, Peterson et al. 2008 ). This region of MZF1 includes the SCAN domain, through which MZF1 also recruits other factors such as ZNF24 to PML-NBs (Noll, Peterson et al. 2008) . Entry into PML-NBs appear to require the post-translational modification by SUMO (small ubiquitin-related modifier) (Heun 2007 , Raman, Nayak et al. 2013 ). SUMO modification (SUMOylation) has recently attracted considerable interest with regard to a role in cancer. Three SUMO paralogs exist in mammalian cells (SUMO1, SUMO2, SUMO3) that can be coupled to lysine residues in target proteins by a conjugation system analogous the one employed in protein ubiquitinylation, with E3 ligases such as Pias1 catalyzing the final coupling step (Bettermann, Benesch et al. 2012 ). The converse process, deSUMOylation is carried out by cysteine-protease-Sentrin-specific-proteases (SENP) (Bettermann, Benesch et al. 2012) . As SUMOylation often inhibits the activity of transcription factors, this process has been considered as a likely tumor suppressing function (Bettermann, Benesch et al. 2012 ). SENP molecules have thus been considered targets in cancer therapy: for instance, SENP1 is expressed to high level in human prostate cancer (Cheng, Bawa et al. 2006) . However the role of these competing processes of SUMOylation and deSUMOylation in cancer appears to be complex and it has for instance been shown recently that modification of proteins including PML and TRIM28/Kap1 by SUMO2 and SUMO3 was increased in metastatic breast cancer (Subramonian, Raghunayakula et al. 2014) . Remarkably in these studies, the increase in SUMOylated PML was accompanied by increased numbers of PML-NBs. It should be noted however that there are many isoforms of PML and these may have different functional consequences in cancer (Jensen, Shiels et al. 2001 ).
SUMOylation of transcription factors has been often associated with gene repression (Stielow, Kruger et al. 2010 , Raman, Nayak et al. 2013 ). The SUMO modification allows recognition by SUMO interacting motifs (SIM) in associated proteins (Raman, Nayak et al. 2013 ). Inhibition of gene transcription after SUMOylation was shown to be due to recruitment of repressor proteins with SIM motifs, including Mi-2 containing complexes, SETDB1 and an LSD1-CoREST-HDAC1 complex (Stielow, Kruger et al. 2010, Tanaka and Saitoh 2010) . SIM domains were found in each of the repressors. In addition SUMO/SIM interactions are critically involved in recruiting transcription factors to PML bodies (Noll, Peterson et al. 2008) . Indeed PML itself contains a functional SIM and is modified by SUMOylation and these domains are involved in its role as a scaffold protein coordinating the assembly of PML-NBs (Cappadocia, Mascle et al. 2015) . Recruitment of the repressor DAXX to the PML-NBs also requires a SIM domain (Chang, Naik et al. 2011 ).
Noll et al suggested that SUMOylation occurred within amino acids 37-128 of MZF1 (Noll, Peterson et al. 2008) . Notably, this sequence contains only one lysine residue at K81. The site of the SUMO recognition site was not ascertained by this group although Noll et al suggested a sequence in the N-terminus-(aa 15-28) (Noll, Peterson et al. 2008 ). In addition, this region contains a consensus SIM site in the N terminus with a motif containing 4 adjacent hydrophobic amino acids-(hydrophobic amino acids at aa 86-90 (LLVL) (Figure 4 ). This site is embedded within a region of negative charge with a serine residue at aa79-again found in many SIMs. Recent studies by Cappadocia et al have shown phosphorylation within the SIM domains of PML and DAXX strongly enhances interactions with SUMO (Cappadocia, Mascle et al. 2015) .
There is strong evidence to indicate that PML-NB may be involved in gene repression and indeed have been also associated with tumor suppression (Jensen, Shiels et al. 2001 ): In addition, the loss of PML-NBs was shown to play a key role in development of acute promyelocytic leukemia (Jensen, Shiels et al. 2001) . The studies of Pandolfi et al showed that knockout of the MZF1 gene led to development of cancer strongly suggesting a potential cancer suppressive activity by MZF1 in this disease (Gaboli, Kotsi et al. 2001 ).
MZF1 SUMOylation might thus play a key role in transcriptional function and it is tempting to speculate that the SUMOylated form may play key roles in gene repression, as with PML.
(6) Upstream activation of MZF1 by phosphorylation and SUMOylation.
In accordance with the phospho-SIM studies of PML one might speculate that S79 of MZF1 could be phosphorylated when MZF1 enter the PML-NBs. S79 is in a region rich in negative charge and could thus be a potential substrate for CK2 that modifies S or T residues within regions of negatively charged amino acids (as is seen with PML). As mentioned above, MZF1 can be activated downstream of TGF-receptor II-activated Erb-B2 in breast cancer through a signaling pathway involving the ERK2 kinase, although the phosphorylation site on MZF1 was not characterized (Rafn, Nielsen et al. 2012) . Screening by mass spectrometry has identified 7 phosphorylated residues in MZF1, including at T169, S177, T210, S256, S274, S294 and S347 in the linker domain /TAD (trans activation domain), S111 in the SCAN domain and T592 in the ZF domain (http://www.phosphosite.org) (Fig. 21) . In addition a screen for CDK4 and CDK6 (Murai, Murakami et al. 1997 ). These phosphorylation sites in murine Mzf1 (S257, 275, 295) occur on similar residues to those found in human MZF1 isoform 1 at S256, 274, 294 (as mentioned above), suggesting possible functional significance for these sites in human MZF1. There are many evidence of phosphorylationdirected SUMO modification (PDSM) with in the consensus PDSM sequence KxExxSP ( Figure 4) ; however, phosphorylation does not inevitably enhance sumoylation of adjacent residues. For instance in the protein TRIM28/Kap1, a factor that associates with Kruppel family ZF proteins, phosphorylation on serine 824 by PIKK family kinases led to loss of Sumo from the N-terminus, inhibition of gene repressive activity and gain of transactivating function (Bunch, Zheng et al. 2014 ) (Iyengar and Farnham 2011) . Interestingly, both TRIM28 and PML belong to the tripartate motif family of factors and TRIM28 has been found to accumulate in Kap1 bodies, structures that have marked similarity to PML-NBs. (Briers, Crawford et al. 2009) 
(7) Regulation of MZF1 by protein-protein interactions
As mentioned above, the SCAN box is a key protein interaction domain allowing SCAN-ZF proteins such as MZF1 to form dimers (Edelstein and Collins 2005) . These interactions include formation of both MZF1 homodimers and heterodimers with other SCAN boxcontaining proteins (Sander, Stringer et al. 2003 , Edelstein and Collins 2005 , Noll, Peterson et al. 2008 . The importance of dimerization for SCAN-ZF transcriptional activity was shown in studies on ZNF174 using GAL4 VP16 two hybrid experimental system. In these studies a ZNF SCAN-VP16 trans-activating fusion construct and a ZNF174 SCAN-GAL4 DNA binding fusion construct were shown to co-activate transcription from a GAL4 binding sites containing reporter construct, indicating that SCAN domain interacts / dimerizes with another SCAN domain in this system and synergistically activates transcription (Williams, Blacklow et al. 1999) .
The presence of a highly conserved SCAN box in the SCAN-ZF family also suggested that a network of interactions between family members may occur through heterodimerization (Edelstein and Collins 2005) . MZF1 for instance has been shown to interact with family members ZNF24, ZNF174 and ZNF202 in SCAN-SCAN box interactions (Noll, Peterson et al. 2008) . Indeed family member ZNF24 was shown to accompany MZF1 into PML-NBs in a SCAN box dependent localization manner (Noll, Peterson et al. 2008) . However, although the SCAN box is highly conserved, not all SCAN domains are able to form dimers indicating some limit to potential partnering between SCAN-ZF members (Edelstein and Collins 2005) .
MZF1 can also interact with a SCAN box-containing protein deficient in ZF domains known as RAZ1 (SCAN-related protein associated with MZF1) or SCAND1 /RAZ108, which are also shown as SCAND1 variant 1 and variant 2 (Sander, Haas et al. 2000) . The exact significance of this interaction is not clear although "zinc fingerless" SCAND1 might attenuate MZF1 signaling through diminished affinity for DNA targets or other interactions (Sander, Haas et al. 2000) . Indeed ZF domains can interact with proteins as well as DNA (Edelstein and Collins 2005) .
Transactivation by MZF1 would likely involve the recruitment of co-activating molecules although little information is available in this regard. However study of the murine Mzf1 paralog indicated its interaction with the SWI/SNF2-type DNA remodeling protein mDomino (Ogawa, Ueda et al. 2003) . mDomino was shown to bind the TAD of Mzf1 and activated transcription of a reporter construct (Ogawa, Ueda et al. 2003 ). In addition human MZF1 was shown to bind to LDOC1, a protein whose expression is reduced in pancreatic and gastric cancer. LDOC1 was shown to encode a leucine zipper domain and SH3 like proline rich domain and this association led to enhancement of apoptosis in Jurkat and K562 cells (Inoue, Takahashi et al. 2005 ).
MZF1 has also been associated with trans-repression of some genes. Takahashi et al showed that MZF1 could bind the co-repressor FHL3 (four and a half Lim domain protein-
3) that interacts with cancer development regulators Smad 2, 3 and 4 (Takahashi, Matsumoto et al. 2005) . Human Fc epsilon RI beta-chain expression was repressed by MZF1, through an element in the fourth intron and transcriptional repression by MZF1 required FHL3 as a cofactor (Takahashi, Matsumoto et al. 2005) . Gene repression by factors such as PML and DAXX has been strongly associated with residence in PML-NBs suggesting the possibility that MZF1 found in such locations might be repressive to target genes.
(8) Conclusions
There is a growing evidence of a role for MZF1 in cancer and certainly its posttranslational modification will influence its role as a gene repressor or activator.
Although the initial studies of MZF1 in malignant progression concentrated on its role in promyelocytic leukemia, the factor now appears to be involved in the etiology of a number of major solid tumor types, such as lung, cervical, breast and colorectal cancer (Tsai, Hwang et al. 2012 ) (Mudduluru, Vajkoczy et al. 2010 , Rafn, Nielsen et al. 2012 , Tsai, Wu et al. 2014 ). These properties may at least partially reflect increases in MZF1 gene copy number and rate of mutation in many cancers (Fig. 1) .
A theme common to many of the studies reviewed here was the finding of MZF1dependent  transcriptional  changes  in  malignant  cell  migration  and invasiveness (Reymann and Borlak 2008 , Mudduluru, Vajkoczy et al. 2010 , Rafn, Nielsen et al. 2012 . These effects of MZF1 at least in promyelocytic leukemia could be mediated through repression of differentiation factors such as CD34 and c-myb or the transactivation of genes encoding effector proteins such as AXL and cathepsin B (Perrotti, Melotti et al. 1995 , Mudduluru, Vajkoczy et al. 2010 , Rafn, Nielsen et al. 2012 . It is interesting to note that a number of studies place MZF1 downstream of TGF-, a factor known to be important in invasion, migration and the EMT phenotype (Massague 2008) .
MZF1 activation by TGF-, may involve one or more of the phosphorylation sites characterized in MZF1 (Driver, Weber et al. 2015) (Fig. 3) .
Although much information has accrued regarding mechanisms of transcriptional regulation by MZF1, major questions remain unanswered. These include the nature of PTMs that regulate function and their coupling to upstream signaling. MZF1 is modified by phosphorylation and SUMOylation as mentioned above, although the significance of these processes is still emerging. Phosphorylation of MZF1 appears to be required for responses to the activating effects of TGF- stimulation (Rafn, Nielsen et al. 2012 , Driver, Weber et al. 2015 . Likewise the role of SUMOylation and entry of MZF1 into PML-NBs may play a significant role in regulation of gene expression in the malignant cell (Noll, Peterson et al. 2008) . Indeed the SUMOylation sites and SUMO-interaction motifs (SIMs) are predicted in human and mouse MZF1 (Fig. 4) . SUMOylation of transcription factors is usually associated with the recruitment of co-repressors, and this process may thus mediate some of the repressive processes orchestrated by MZF1 in differentiation and cancer (Stielow, Kruger et al. 2010, Tanaka and Saitoh 2010) .
Other questions related to MZF1 and its role in cancers that may require study include:
( Recruitment of co-activators and co-repressors by MZF1. Murine Mzf1 is known to interact with the chromatin remodeling factor mDomino, a protein that can function to insert the non-canonical histone H2AZ into chromatin (Ogawa, Ueda et al. 2003 , Fujii, Ueda et al. 2010 ) Elevated levels of H2AZ are associated with rapid transcription (Redon, Pilch et al. 2002) . Sumoylated MZF1 might be expected to interact with the SIM domains of gene repressors as described above, although this connection has not been formally proven. Future studies will address cell signaling in cancer and association of activators and repressors with MZF1.
(3) Global interactions of MZF1 with the human genome.
Determining the global interactions of MZF1 with the genomes of normal and malignant cells is clearly an important next step in the project of assessing the importance of this factor and its transcriptional targets in cancer.
Answers to these questions may permit us to consider strategies to targeting this intriguing factor in cancer or assessing MZF1 as a biomarker for cancer diagnosis and prognosis. Phosphositeplus. Two phospho-directed SUMO sites at K23/S27 and K184/S187 were predicted using SUMOplot and GPS-SUMO at high scores (see later figure) . MZF1 isoform 2, which is generated by alternative splicing, consists of the SCAN box and the regulatory domain, in which amino acids 259-290 including serine 274 were replaced (serines were shown in red). MZF1 isoform 3 consists of the regulatory region and ZF motifs (9 ZFs).
Legends
This 3rd isoform was validated in mouse in the NCBI protein database, but recently deleted in human. Validated MZF1 isoform 2 in mouse is 542 aa, while human MZF1 isoform 2 is 290 aa. Natural variants and a sequence conflicts were mapped. presumably acetylation and ubiquitinylation (Noll, Peterson et al. 2008 ).
SUMO1modification of MZF1 enables interaction with SUMO-interaction motif (SIM)containing proteins such as PML (Noll, Peterson et al. 2008) . Enzymes, transcription factors and other molecules stored in PML-NBs could potentially further give rise to further PTMs in MZF1 and modulate its function in gene regulation. Eguchi, Prince, Wegiel, SKC Figure 1 
